课题基金 / 基金详情

项目摘要

项目成果

PETER WESTERVELT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT The goal of the Biospecimen Processing Core (BPC, Core A) is to provide high-quality, clinically annotated biospecimens to all five research projects in this SPORE application as well as ongoing and future SPORE- sponsored DRP and CEP projects, and to serve as an unparalleled biospecimen resource to the broader cancer research community. The BPC will be responsible for the identification and enrollment of every patient referred to the Siteman Cancer Center with newly diagnosed and relapsed hematologic malignancy (excluding multiple myeloma). Biospecimens from these patients will be collected, processed, and stored by leveraging the extensive infrastructure of the Siteman Cancer Center Tissue Procurement Core (TPC), a CAP-accredited biorepository with over 15 years of experience in biospecimen banking. Clinical data will be collected prospectively by integrating with and extending the mission of an existing Clinical Database Core (CDC), previously established as part of the Genomics of AML (GAML) Program Project to serve as a platform for the investigation of genetic mutations associated with the pathogenesis of MDS and AML. As such, Core A will continue to supplement Cancer Center resources with focused expertise and effort to comprehensively collect, annotate, quality review, and distribute biospecimens specifically for translational leukemia and leukemia- related cancer research. Specific Aims include: Specific Aim 1. To provide expertise in biobanking and clinical annotation to specifically support projects 1- 5 in this SPORE application. Specific Aim 2. To provide an on-going, high quality, clinically annotated biospecimen resource of hematological malignancy patient biospecimens for other translational research projects both within and external to this SPORE program. Specific Aim 3: To create a comprehensive and transparent plan to catalog collected biospecimens and facilitate their distribution to the broader scientific community of hematologic malignancy investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
  • 批准号:
    10430084
  • 项目类别:
  • 资助金额:
    $16.57万
  • 财政年份:
    2017
  • 负责人:
    PETER WESTERVELT
  • 依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
  • 批准号:
    9385676
  • 项目类别:
  • 资助金额:
    $14.89万
  • 财政年份:
    2017
  • 负责人:
    PETER WESTERVELT
  • 依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
  • 批准号:
    10165782
  • 项目类别:
  • 资助金额:
    $16.96万
  • 财政年份:
    2017
  • 负责人:
    PETER WESTERVELT
  • 依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
  • 批准号:
    9535449
  • 项目类别:
  • 资助金额:
    $17.05万
  • 财政年份:
    2017
  • 负责人:
    PETER WESTERVELT
  • 依托单位:
海外基金